...
首页> 外文期刊>Indian Journal of Pathology and Microbiology >Secretory cell outgrowths, p53 signatures, and serous tubal intraepithelial carcinoma in the fallopian tubes of patients with sporadic pelvic serous carcinoma
【24h】

Secretory cell outgrowths, p53 signatures, and serous tubal intraepithelial carcinoma in the fallopian tubes of patients with sporadic pelvic serous carcinoma

机译:散发性盆腔浆液性癌患者输卵管中的分泌细胞增生,p53信号和浆液性输卵管上皮内癌

获取原文
           

摘要

Context: High-grade serous carcinomas of ovarian, tubal, and peritoneal origin are together referred as pelvic serous carcinoma. The fallopian tubes, ovarian surfaceepithelium, and the tuboperitoneal junctional epithelium are all implicated in pelvic serous carcinogenesis. Aims: The aim of this study is to identify putative precursorlesions of serous carcinoma including secretory cell outgrowths (SCOUTs), serous tubal intraepithelial carcinoma (STIC), and p53 signatures and assign its probablesite of origin. Settings and Design: Prospective case-control study of consecutive specimen comprising 32 serous carcinomas and 31 controls (10 normal adnexa,10 benign and 6 atypically proliferative surface epithelial tumors, and 5 other carcinomas). Subjects and Methods: Sectioning and extensive examination of thefimbrial end (SEE-FIM) protocol along with immunohistochemistry for Bcl-2, p53, and Ki-67 was employed for evaluating invasive carcinoma and precursor lesionsin cases versus controls. Results: SCOUT, p53 signatures, and STIC were most frequent in the serous carcinomas. p53 signatures and STIC were always seen in thefimbrial end. STICs were exclusively present in serous carcinomas, more common in ipsilateral tubes of cases with dominant ovarian mass. Multifocal p53 signatureswith STIC were seen in 7 (21.9%) cases. STIC was present with or without an invasive carcinoma in 25% and in 6.25% of cases of pelvic serous carcinomas,respectively. The junctional epithelia did not show any lesion in any group. Conclusions: SEE-FIM protocol is recommended for evaluation of sporadicpelvic(ovarian/tubal/peritoneal) serous carcinoma. Based on the presence of STIC or invasive carcinoma, nearly 60% of all pelvic serous carcinomas are of fallopian tubalorigin.
机译:背景:卵巢,输卵管和腹膜起源的高级浆液性癌统称为骨盆浆液性癌。输卵管,卵巢表面上皮和肾小管腹膜上皮均与盆腔浆液性癌变有关。目的:本研究的目的是鉴定浆液性癌的推定先兆,包括分泌细胞增生(SCOUTs),浆液性输卵管上皮内癌(STIC)和p53标记,并确定其可能的起源。设置和设计:连续样本的前瞻性病例对照研究,包括32例浆液性癌和31例对照(10例正常附件,10例良性和6例非典型增生性表面上皮性肿瘤以及5例其他癌)。研究对象和方法:对Bcl-2,p53和Ki-67的纤维末端(SEE-FIM)方案以及免疫组织化学进行切片和广泛检查,以评估与对照组相比侵袭性癌和前体病变。结果:浆液性癌中SCOUT,p53标记和STIC最常见。 p53签名和STIC总是在纤维末端可见。 STIC仅存在于浆液性癌中,在卵巢占优势的病例的同侧管中更常见。在7例(21.9%)病例中观察到STIC多灶性p53签名。 25%和6.25%的盆腔浆液性癌病例中,有或没有浸润性癌的病例均为STIC。交界上皮在任何组中均未显示任何病变。结论:推荐使用SEE-FIM方案评估散发性盆腔(卵巢/输卵管/腹膜)浆液性癌。基于STIC或浸润性癌的存在,所有盆腔浆液性癌中将近60%为输卵管输卵管癌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号